Match 150mg Injection contains Arteether 150mg, a semi-synthetic derivative of artemisinin, used primarily for the treatment of severe and complicated malaria caused by Plasmodium falciparum. Arteether exhibits rapid schizonticidal activity against the erythrocytic stages of the parasite, leading to prompt reduction of parasitemia and clinical symptoms. This injectable formulation is indicated for patients who are unable to take oral antimalarials or in cases where rapid therapeutic response is critical. The drug is administered intramuscularly, ensuring rapid absorption and onset of action. Arteether acts by generating reactive oxygen species and interfering with the parasite's intracellular processes, resulting in parasite death. It is generally well tolerated, though adverse effects may include dizziness, nausea, headache, and transient elevation of liver enzymes. Caution is advised in patients with known hypersensitivity to artemisinin derivatives and in those with pre-existing cardiac conditions, as rare cardiotoxicity has been reported. Use during pregnancy should be considered only if the potential benefits outweigh the risks. Match 150mg Injection should be used under strict medical supervision, with appropriate monitoring of clinical and parasitological response to ensure effective treatment and minimize the risk of resistance development.